Access Keys:
Skip to content (Access Key - 0)

Center for Cancer Research National Cancer Institute
NCI Drug Development Collaborative

The Drug Development Collaborative provides the infrastructure to enhance collaborative basic, translational, and clinical research on molecular targets or pathways. The DDC along with the the Molecular Targets Laboratory strive to provide intramural investigators with assistance in the development of screening assays to identify small-molecule inhibitors and biologic agents that interact with molecular targets including macromolecular, protein-based, or nanotech agents, and to support the pre-clinical development of promising molecularly targeted lead compounds.

The Drug Development Collaborative (DDC) is focused on bringing CCR PI-initiated small molecules from the bench to development via the NCI Experimental Therapeutics (NExT) Program with DCTD.

Our mission is:

  • To identify and validate important molecular targets in cancer and AIDS
  • To sponsor early drug development in the Intramural Research Program (IRP)
  • To facilitate collaboration and communication
If you have identified a compound you feel might be beneficial to develop, you must:
 

To view the NCI tutorial on understanding targeted therapies click here NCI molecular targets

 

Next page

Added by Shilling, Jeffrey (NIH/NCI) [E] , last edited by Boersma, Brenda (NIH/NCI) [E] on Apr 15, 2013 14:20